Sanofi SA logo

GCVRZ - Sanofi SA Share Price

$0.58 0.0  0.9%

Last Trade - 21/10/19

Sector
Healthcare
Size
Large Cap
Market Cap £89.19bn
Enterprise Value £106.52bn
Revenue £30.69bn
Position in Universe 75th / 6413
Bullish
Bearish
Unlock GCVRZ Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

GCVRZ Revenue Unlock GCVRZ Revenue

Net Income

GCVRZ Net Income Unlock GCVRZ Revenue

Normalised EPS

GCVRZ Normalised EPS Unlock GCVRZ Revenue

PE Ratio Range

GCVRZ PE Ratio Range Unlock GCVRZ Revenue

Dividend Yield Range

GCVRZ Dividend Yield Range Unlock GCVRZ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GCVRZ EPS Forecasts Unlock GCVRZ Revenue
Profile Summary

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated May 11, 1994
Public Since July 1, 2002
No. of Shareholders: n/a
No. of Employees: 104,226
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange NASDAQ Global Market (Dual Listing)
Shares in Issue 1,251,999,921
Free Float (0.0%)
Eligible for
ISAs
SIPPs
GCVRZ Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to GCVRZ
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.